HDT Bio Corp., a Seattle, WA-based biotechnology company enabling global access to immunotherapies for oncology and infectious disease, closed its seed financing round totaling ~$3m.
The round was co-led by Zoic Capital and joined by angel investors from multiple biotechnology hubs.
Led by Dr. Steven Reed, CEO, HDT Bio is developing biotherapeutics for oncology and infectious disease applications. One of the company’s core technologies, RNA/LION™, combines formulation and adjuvant ingredients to stabilize and deliver RNA to the immune system to stimulate responses for therapy or vaccination.
The company intends to use the funds for the continued development of its COVID-19 vaccine candidate, HDT-301. The vaccine is slated to enter clinical trials in Q4 2020 in partnership with the NIH/NIAID.
In addition to HDT-301, the company has a variety of other immunotherapy technologies highlighting different approaches to immune stimulation or modulation.